GOLDSMITH MARK A 4

What Happened

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines (RVMD), exercised options on Feb 6, 2026 to acquire 24,010 shares at an exercise price of $0.54 per share, paying $12,965 in total. The same number of shares (24,010) is also reported as a zero-dollar derivative disposition on the same date.

Key Details

• Transaction date: 2026-02-06.
• Exercise: 24,010 shares acquired @ $0.54; total cash paid = $12,965.
• Matching disposition: 24,010 shares reported disposed at $0.00 (derivative).
• Shares owned after transaction: Not specified in the filing; footnote F1 notes ownership includes 168,763 restricted stock units.
• Holdings reported via trusts: F2–F4 indicate certain holdings are held by family revocable trusts.
• Filing date: Form 4 filed 2026-02-10 (appears timely based on the Feb 6 transaction date).

Context

• The filing shows an option exercise (derivative transaction). The reported zero-dollar disposal typically indicates shares were surrendered or withheld (commonly to cover taxes or exercise-related obligations) rather than sold for cash; no cash sale proceeds are reported. This is a routine insider exercise and does not by itself indicate a change in the CEO’s view of the company.